Search Results

Mawi DNA Technologies announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s iSWAB-Respiratory Tract Sample Collection Media-Extraction Less™ (iSWAB-RC-EL).

Mawi DNA Technologies announced that it has signed Memorandum of Understanding agreements with the Moroccan Ministry of Investment, Convergence and Evaluation of Public Policies as well as with the Moroccan Ministry of Industry and Commerce to explore a joint venture with Mawi’s local partner BIOTESSIA to establish a state-of-the-art manufacturing facility in Morocco to serve the African market.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, and Alphazyme LLC, a Maravai LifeSciences company and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies’ previously announced Linea™ RNAP manufacturing scale-up agreement.

Mawi DNA Technologies (Mawi), a medical device company focusing on the development of innovative technologies for biosampling, has launched the NextSWAB™, a 100% medical-grade plastic swab designed and manufactured in the US.

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced that it completed exclusive commercial licensing of a gene editing technology from the University of California Berkeley.

Mawi DNA Technologies has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to Japan.

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.